Separating the direct effects of traits on atherosclerotic cardiovascular disease from those mediated by type 2 diabetes

被引：0
|
作者：
Venexia M. Walker
Marijana Vujkovic
Alice R. Carter
Neil M. Davies
Miriam S. Udler
Michael G. Levin
George Davey Smith
Benjamin F. Voight
Tom R. Gaunt
Scott M. Damrauer
机构：
[1] MRC University of Bristol Integrative Epidemiology Unit,Bristol Medical School: Population Health Sciences
[2] University of Bristol,Department of Surgery
[3] University of Pennsylvania Perelman School of Medicine,Department of Medicine
[4] University of Pennsylvania Perelman School of Medicine,K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU
[5] Norwegian University of Science and Technology,Center for Genomic Medicine
[6] Massachusetts General Hospital,Division of Cardiovascular Medicine
[7] University of Pennsylvania Perelman School of Medicine,Department of Systems Pharmacology and Translational Therapeutics
[8] Corporal Michael Crescenz VA Medical Center,Department of Genetics
[9] University of Pennsylvania Perelman School of Medicine,Institute of Translational Medicine and Therapeutics
[10] University of Pennsylvania Perelman School of Medicine,undefined
[11] University of Pennsylvania Perelman School of Medicine,undefined
来源：
Diabetologia | 2022年 / 65卷
关键词：
Atherosclerotic cardiovascular disease; Coronary artery disease; Direct effect; Genome-wide association study; Indirect effect; Mediation; Mendelian randomisation; Peripheral artery disease; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：790 / 799
页数：9
相关论文
共 50 条
  • [31] Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial
    Odutayo, Ayodele
    Cosentino, Francesco
    Pratley, Richard E.
    Dagogo-Jack, Samuel
    McGuire, Darren K.
    Frederich, Robert
    Fu, Wei
    Cannon, Christopher P.
    Cherney, David Z. I.
    DIABETES OBESITY & METABOLISM, 2024, 26 (08): : 3478 - 3481
  • [32] HYPOGLYCEMIA AND CV OUTCOMES IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL
    Pratley, Richard E.
    McGuire, Darren K.
    Fu, Wei
    Cannon, Christopher P.
    Cherney, David Z. I.
    Cosentino, Francesco
    Liu, Jie
    Frederich, Robert
    Mancuso, James P.
    Dagogo-Jack, Samuel
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2062 - 2062
  • [33] Clinical Update: Cardiovascular Disease in Diabetes Mellitus Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations
    Wang, Cecilia C. Low
    Hess, Connie N.
    Hiatt, William R.
    Goldfine, Allison B.
    CIRCULATION, 2016, 133 (24) : 2459 - 2502
  • [34] Pro-B-Type Natriuretic Peptide Strongly Predicts Future Cardiovascular Events in Cardiovascular Disease Patients with Type 2 Diabetes as Well as in Those Without Type 2 Diabetes
    Saely, Christoph H.
    Vonbank, Alexander
    Heinzle, Christine
    Zanolin, Daniela
    Larcher, Barbara
    Mader, Arthur
    Leiherer, Andreas
    Muendlein, Axel
    Drexel, Heinz
    DIABETES, 2018, 67
  • [35] PRO-B-TYPE NATRIURETIC PEPTIDE STRONGLY PREDICTS FUTURE CARDIOVASCULAR EVENTS IN CARDIOVASCULAR DISEASE PATIENTS WITH TYPE 2 DIABETES AS WELL AS IN THOSE WITHOUT TYPE 2 DIABETES
    Saely, C. H.
    Vonbank, A.
    Heinzle, C.
    Purin, D.
    Larcher, B.
    Mader, A.
    Leiherer, A.
    Muendlein, A.
    Drexel, H.
    ATHEROSCLEROSIS, 2019, 287 : E189 - E189
  • [36] Pro-B-type natriuretic peptide strongly predicts future cardiovascular events in cardiovascular disease patients with type 2 diabetes as well as in those without type 2 diabetes
    Saely, C. H.
    Vonbank, A.
    Heinzle, C.
    Zanolin, D.
    Larcher, B.
    Mader, A.
    Ebner, K-M.
    Leiherer, A.
    Muendlein, A.
    Drexel, H.
    WIENER KLINISCHE WOCHENSCHRIFT, 2018, 130 : 100 - 100
  • [37] Pro-B-type natriuretic peptide strongly predicts future cardiovascular events in cardiovascular disease patients with type 2 diabetes as well as in those without type 2 diabetes
    Mader, Arthur
    Saely, Christoph
    Vonbank, Alexander
    Heinzle, Christine
    Zanolin-Purin, Daniela
    Larcher, Barbara
    Leiherer, Andreas
    Muendlein, Doz Axel
    Drexel, Heinz
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2019, 49 : 156 - 156
  • [38] The correlation analysis between serum MSTN and atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus
    董俐
    China Medical Abstracts(Internal Medicine), 2024, 41 (03) : 160 - 161
  • [39] Atherosclerotic Cardiovascular Disease in Type 2 Diabetes: A Retrospective, Observational Study of Economic and Clinical Burden in Sweden
    Carlsson, Katarina Steen
    Faurby, Mads
    Nilsson, Kristoffer
    Wolden, Michael Lyng
    DIABETES THERAPY, 2023, 14 (08) : 1357 - 1372
  • [40] Atherosclerotic cardiovascular disease among migrants with type 2 diabetes: a nationwide register-based study
    Andersen, G. S.
    Byberg, S.
    Bjorkman, A. -S. D.
    Isaksen, A. A.
    Amadid, H.
    Carstensen, B.
    Jorgensen, M. E.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S142 - S143
12345